Home > News > featured news > TransPerfect Life Sciences Introduces Trial Interactive CTMS Solution

PHARMA TECH

TransPerfect Life Sciences Introduces Trial Interactive CTMS Solution

Trial Interactive | November 12, 2021

TransPerfect Life Sciences, a leading provider of services and technologies to support global clinical trials and product development for the biopharmaceutical industry, announced the release of the Trial Interactive (TI) Clinical Trial Management System (CTMS). This release marks the industry's only mobile-first CTMS, placing important actions and information at the fingertips of study managers and CRAs and supporting a full author-to-archive process.

Trial Interactive delivers user-friendly document and trial management solutions to help pharmaceutical, biotechnology, medical device, and contract research organizations (CROs) effectively streamline product development life cycles. The platform improves speed, quality, and compliance across site identification, site feasibility, study start-up, site personnel training, regulated content management, eISF, and eTMF management. The addition of TI CTMS enables a single source of truth across the entire life cycle, providing transparency into Trial Interactive solutions and any sponsor or CRO systems of record. A fully connected solution, Trial Interactive offers fast-to-implement and cost-effective solutions in a secure 21 CFR Part 11-compliant environment.

Designed by clinical professionals for clinical professionals, TI CTMS benefits include

  • World-Class User Experience – The time-saving and pain-free mobile-first interface, with full-text and segmented metadata search, flexible filtering and exports, dark mode, and one-click navigation, creates the industry's friendliest user experience.
     
  • By Clinical, for Clinical – Enjoy greater efficiency without the hassle, and get started quickly with no heavy configuration required and best practices built into the default configuration.
     
  • True SaaS Solution – TI CTMS is a single-study or enterprise SaaS solution developed by experts. TransPerfect's award-winning service teams support rapid implementation plans with full validation.
     
  • Enterprise Ready – With the flexibility to align with large-scale operations, TI CTMS enables enterprises with complex study teams to easily update the system to meet unique requirements and have access to a comprehensive web services API supporting third-party integrations.
     
  • Author-to-Archive Platform – Streamline processes and oversight with content management solutions supporting the workflow of documents across the life cycle from site and study personnel to the eTMF in one seamless process.

As clinical operations become more decentralized, TI CTMS continues Trial Interactive's mission of providing practical innovation to improve the efficiency of global clinical processes while reducing costs. 

"Having consulted with many organizations and colleagues over the years about CTMS, we've recognized common challenges like time-consuming configurations, difficult navigation, and user experiences that are clearly developed without the input of clinical operations experts. The end result is that existing platforms have fallen short of the features that study managers and CRAs really needTI CTMS was built by clinical professionals for clinical professionals and cuts configuration times while delivering powerful capabilities in a clean user experience that perfectly addresses the needs of sponsors and CROs."


 Michael Smyth, Division President of TransPerfect Life Sciences

TransPerfect President and CEO Phil Shawe stated, "The launch of TI CTMS comes at a time when conducting remote and decentralized clinical trials is more important than ever. The CTMS is connected to our eTMF and other platform solutions to deliver a mobile-first experience that ensures study teams can work effectively and at scale from any location."

About Trial Interactive
TransPerfect's Trial Interactive is an industry leader in practical eClinical innovation that simplifies and automates clinical processes for sponsors, CROs, and sites around the world. The 21 CFR part 11 compliant unified platform delivers an author to archive collaboration experience with solutions for clinical document management, site selection, site activation, eLearning, compliance training, quality, and more with seamless solution interoperability and indexing to the eTMF. Trial Interactive is consistently selected by clinical professionals for providing the most comprehensive yet intuitive experience with the most complete offering of technology and expert TMF services. Trial Interactive helps study teams streamline their operations by cutting unnecessary expenses, expediting timelines, reducing compliance risks, and improving operational excellence.

About TransPerfect Life Sciences
TransPerfect Life Sciences specializes in supporting global development and commercialization of drugs, treatments, and devices designed to improve and save lives. Our comprehensive solutions include eTMF and eClinical technologies, paper TMF migration, pharmacovigilance and safety solutions, translation and language services, and call center support. With offices in over 100 cities worldwide, TransPerfect is the ideal partner to ensure that your global launch makes a global impact.

About TransPerfect
TransPerfect is the world's largest provider of language and technology solutions for global business. From offices in over 100+ cities on six continents, TransPerfect offers a full range of services in 170+ languages to clients worldwide. More than 5,000 global organizations employ TransPerfect's GlobalLink® technology to simplify management of multilingual content. With an unparalleled commitment to quality and client service, TransPerfect is fully ISO 9001 and ISO 17100 certified. TransPerfect has global headquarters in New York, with regional headquarters in London and Hong Kong.

Spotlight

We are EQL Pharma

EQL Pharma AB (publ) is a pharmaceuticals company based out of Skåne County, Sweden.

More featured news

Spotlight

We are EQL Pharma

EQL Pharma AB (publ) is a pharmaceuticals company based out of Skåne County, Sweden.

Related News

BUSINESS INSIGHTS, PHARMA TECH

West Expands Collaboration with Corning and Introduces First Product

West Pharmaceutical Services | February 13, 2023

West Pharmaceutical Services, Inc., a leading global innovative injectable drug administration solutions provider, recently announced the expansion of its remarkable collaboration with Corning Incorporated, which now includes exclusive distribution rights for Corning Valor® Glass vials as well as the launch of its first product, West Ready Pack™ with Corning Valor® RTU Vials employing SG EZ-fill® technology. The West Ready Pack™ with Corning Valor® RTU Vials integrates West's highest quality NovaPure® stoppers, Flip-Off® CCS (Certified, Clean, Sterilized) seals and Corning's best-in-class Valor® RTU Vials with SG EZ-fill® technology into a complete containment solution to assist in the introduction of parenteral drugs and diagnostics to the market. West announced its agreement with Corning in January 2022, which includes a multimillion-dollar investment to develop Corning's Valor® Glass technology to improve patient safety and increase access to life-saving therapies. This strategic alliance provides premier elastomer-glass system solutions for injectable drug storage and delivery. In addition, West and Corning intend to collaborate to develop the next generation of integrated packaging and delivery system solutions. Valor® RTU Vials with SG EZ-fill® technology improve medication storage and distribution, enable more reliable access to important medicines for public health, and maximize production efficiency. This pharmaceutical glass was explicitly created to handle the problems of modern industrial procedures. The Ready Pack™ mixture of NovaPure® stoppers, Flip-Off® CCS seals, and Valor® RTU Vials with SG EZ-fill® technology offers drug developers the following advantages Proven Container Closure Integrity (CCI), which includes the ability to sustain cold storage CCI when cooled to and kept at -80 degrees Celsius; Ready-to-use sterile format that may be introduced immediately into filling operations, avoiding the requirement for component preparation; Premium components with the most stringent particle requirements available from West; and Availability in volumes appropriate for small-scale filling operations with continuity to quantity alternatives for large-scale commercial operations. About West Pharmaceutical Services Founded in 1923, West Pharmaceutical Services, Inc. is a leading high-quality, innovative injectable solutions and services provider. It is a trusted partner to both established and emergent drug producers and contributes to the safe, effective containment and delivery of life-enhancing and life-saving medications to patients. West supports its clients by supplying over 45 billion components and devices each year, with a team of approximately 10000 members spread across 50 facilities globally. Headquartered in Exton, Pennsylvania, the company has been operating for over a century and achieved $2.83 billion in net sales in the fiscal year 2021.

Read More

BUSINESS INSIGHTS, PHARMA TECH

Avacta Completes Fourth Dose Escalation in AVA6000 Phase 1 Clinical Study

Avacta | January 23, 2023

Avacta Group plc, a leading life sciences company focused on developing innovative, targeted oncology medicines and powerful diagnostics, recently announced that AVA6000 has maintained a very favorable safety profile in the fourth dose cohort of the ALS-6000-101 dose escalation phase 1 clinical trial. Furthermore, analysis of tumor samples acquired from six patients across multiple cohorts shows that doxorubicin is being released within the tumor tissue, supporting the pre|CISIONTM technology's tumor-targeting capability. Patients in cohort 4 continue to tolerate AVA6000 well, with a significant decrease in the occurrence and severity of the commonly associated toxicities with the administration of traditional doxorubicin treatment. Nausea, vomiting, Alopecia, mucositis, myelosuppression, and cardiotoxicity are all among the typical toxicities. Notably, the typical drug-related cardiotoxicity of doxorubicin was not found even at the highest dosage levels in group 4, equivalent to more than double the standard dose of doxorubicin. In order to confirm the release of the active chemotherapy, doxorubicin, in tumor tissue, several tumor biopsies acquired from patients in different cohorts have been analyzed. This analysis demonstrates that AVA6000 targets the release of doxorubicin to tumor tissue at therapeutic levels that are significantly higher than those detected in the bloodstream at the same time point. To date, AVA6000 has been administered to 19 patients with advanced and/or metastatic solid tumors who were enrolled across four groups. Based on the very favorable safety profile of AVA6000 in the study thus far, the Safety Data Monitoring Committee (SDMC) has recommended that the study be extended to higher dose cohorts in order to identify a maximum tolerated dose (MTD) required to inform dosing levels for the phase 1b and future studies. The Company anticipates completing these additional cohorts within the first half of 2023. About Avacta Avacta is a healthcare group that promotes human health and well-being by creating new cancer treatments and powerful in vitro diagnostics. Its mission is to create the future of medicine by producing safe and effective medications as well as high-performance diagnostics using its unique Affimer® and pre|CISIONᵀᴹ platforms. By merging these two platforms, the Company is constructing a pipeline of innovative cancer therapeutics to fulfil its goal of developing successful treatments for all cancer patients, including those who do not react to current immunotherapies.

Read More

BUSINESS INSIGHTS, PHARMACY MARKET

Caris Life Sciences and Xencor Expand Target Discovery Collaboration

Caris Life Sciences and Xencor | January 06, 2023

Caris Life Sciences®, a molecular science and technology company, and Xencor, Inc., a clinical-stage biopharmaceutical company, have announced that they will work more closely together to research, develop, and sell new bispecific and multispecific XmAb® antibodies. This expanded relationship will boost the number of targets and cancer types that Caris will investigate with Caris Discovery, a proprietary multi-omics discovery engine platform. The foundation for drug candidate development on Xencor's XmAb platform will be novel targets and their accompanying validation packages. Under the terms of the new contract, Xencor will receive worldwide commercial rights to study, develop, and market products aimed at up to three targets discovered through collaboration. In addition, Caris will get an upfront payment and may receive up to $187 million in commercial milestone payments and development. The company will also be eligible for royalties on the net sales of products commercialized as a result of the agreement, as well as future rights for molecular profiling and companion diagnostics. Caris Discovery leverages the collective force of its unmatched platform by combining the data generated from the primary patient tissues' molecular interrogation using ADAPT™, which integrates the company's extensive catalog of molecular and clinical data. About Caris Life Sciences Caris Life Sciences® is a Texas-based molecular science firm revolutionizing healthcare. Its market-leading molecular profiling products analyze DNA, RNA, and proteins to produce a molecular blueprint. This plan shows how patients, doctors, and researchers can use the information to improve outcomes and save lives. The company also uses cutting-edge algorithms for artificial intelligence (AI) and machine learning (ML) to improve precision medicine. About Xencor Xencor develops modified antibodies and cytokines for cancer and autoimmune illnesses. More than 20 XmAb® candidates are in clinical development while three are sold by partners. The company’s XmAb technology modifies protein structures to create new therapeutic pathways.

Read More

BUSINESS INSIGHTS, PHARMA TECH

West Expands Collaboration with Corning and Introduces First Product

West Pharmaceutical Services | February 13, 2023

West Pharmaceutical Services, Inc., a leading global innovative injectable drug administration solutions provider, recently announced the expansion of its remarkable collaboration with Corning Incorporated, which now includes exclusive distribution rights for Corning Valor® Glass vials as well as the launch of its first product, West Ready Pack™ with Corning Valor® RTU Vials employing SG EZ-fill® technology. The West Ready Pack™ with Corning Valor® RTU Vials integrates West's highest quality NovaPure® stoppers, Flip-Off® CCS (Certified, Clean, Sterilized) seals and Corning's best-in-class Valor® RTU Vials with SG EZ-fill® technology into a complete containment solution to assist in the introduction of parenteral drugs and diagnostics to the market. West announced its agreement with Corning in January 2022, which includes a multimillion-dollar investment to develop Corning's Valor® Glass technology to improve patient safety and increase access to life-saving therapies. This strategic alliance provides premier elastomer-glass system solutions for injectable drug storage and delivery. In addition, West and Corning intend to collaborate to develop the next generation of integrated packaging and delivery system solutions. Valor® RTU Vials with SG EZ-fill® technology improve medication storage and distribution, enable more reliable access to important medicines for public health, and maximize production efficiency. This pharmaceutical glass was explicitly created to handle the problems of modern industrial procedures. The Ready Pack™ mixture of NovaPure® stoppers, Flip-Off® CCS seals, and Valor® RTU Vials with SG EZ-fill® technology offers drug developers the following advantages Proven Container Closure Integrity (CCI), which includes the ability to sustain cold storage CCI when cooled to and kept at -80 degrees Celsius; Ready-to-use sterile format that may be introduced immediately into filling operations, avoiding the requirement for component preparation; Premium components with the most stringent particle requirements available from West; and Availability in volumes appropriate for small-scale filling operations with continuity to quantity alternatives for large-scale commercial operations. About West Pharmaceutical Services Founded in 1923, West Pharmaceutical Services, Inc. is a leading high-quality, innovative injectable solutions and services provider. It is a trusted partner to both established and emergent drug producers and contributes to the safe, effective containment and delivery of life-enhancing and life-saving medications to patients. West supports its clients by supplying over 45 billion components and devices each year, with a team of approximately 10000 members spread across 50 facilities globally. Headquartered in Exton, Pennsylvania, the company has been operating for over a century and achieved $2.83 billion in net sales in the fiscal year 2021.

Read More

BUSINESS INSIGHTS, PHARMA TECH

Avacta Completes Fourth Dose Escalation in AVA6000 Phase 1 Clinical Study

Avacta | January 23, 2023

Avacta Group plc, a leading life sciences company focused on developing innovative, targeted oncology medicines and powerful diagnostics, recently announced that AVA6000 has maintained a very favorable safety profile in the fourth dose cohort of the ALS-6000-101 dose escalation phase 1 clinical trial. Furthermore, analysis of tumor samples acquired from six patients across multiple cohorts shows that doxorubicin is being released within the tumor tissue, supporting the pre|CISIONTM technology's tumor-targeting capability. Patients in cohort 4 continue to tolerate AVA6000 well, with a significant decrease in the occurrence and severity of the commonly associated toxicities with the administration of traditional doxorubicin treatment. Nausea, vomiting, Alopecia, mucositis, myelosuppression, and cardiotoxicity are all among the typical toxicities. Notably, the typical drug-related cardiotoxicity of doxorubicin was not found even at the highest dosage levels in group 4, equivalent to more than double the standard dose of doxorubicin. In order to confirm the release of the active chemotherapy, doxorubicin, in tumor tissue, several tumor biopsies acquired from patients in different cohorts have been analyzed. This analysis demonstrates that AVA6000 targets the release of doxorubicin to tumor tissue at therapeutic levels that are significantly higher than those detected in the bloodstream at the same time point. To date, AVA6000 has been administered to 19 patients with advanced and/or metastatic solid tumors who were enrolled across four groups. Based on the very favorable safety profile of AVA6000 in the study thus far, the Safety Data Monitoring Committee (SDMC) has recommended that the study be extended to higher dose cohorts in order to identify a maximum tolerated dose (MTD) required to inform dosing levels for the phase 1b and future studies. The Company anticipates completing these additional cohorts within the first half of 2023. About Avacta Avacta is a healthcare group that promotes human health and well-being by creating new cancer treatments and powerful in vitro diagnostics. Its mission is to create the future of medicine by producing safe and effective medications as well as high-performance diagnostics using its unique Affimer® and pre|CISIONᵀᴹ platforms. By merging these two platforms, the Company is constructing a pipeline of innovative cancer therapeutics to fulfil its goal of developing successful treatments for all cancer patients, including those who do not react to current immunotherapies.

Read More

BUSINESS INSIGHTS, PHARMACY MARKET

Caris Life Sciences and Xencor Expand Target Discovery Collaboration

Caris Life Sciences and Xencor | January 06, 2023

Caris Life Sciences®, a molecular science and technology company, and Xencor, Inc., a clinical-stage biopharmaceutical company, have announced that they will work more closely together to research, develop, and sell new bispecific and multispecific XmAb® antibodies. This expanded relationship will boost the number of targets and cancer types that Caris will investigate with Caris Discovery, a proprietary multi-omics discovery engine platform. The foundation for drug candidate development on Xencor's XmAb platform will be novel targets and their accompanying validation packages. Under the terms of the new contract, Xencor will receive worldwide commercial rights to study, develop, and market products aimed at up to three targets discovered through collaboration. In addition, Caris will get an upfront payment and may receive up to $187 million in commercial milestone payments and development. The company will also be eligible for royalties on the net sales of products commercialized as a result of the agreement, as well as future rights for molecular profiling and companion diagnostics. Caris Discovery leverages the collective force of its unmatched platform by combining the data generated from the primary patient tissues' molecular interrogation using ADAPT™, which integrates the company's extensive catalog of molecular and clinical data. About Caris Life Sciences Caris Life Sciences® is a Texas-based molecular science firm revolutionizing healthcare. Its market-leading molecular profiling products analyze DNA, RNA, and proteins to produce a molecular blueprint. This plan shows how patients, doctors, and researchers can use the information to improve outcomes and save lives. The company also uses cutting-edge algorithms for artificial intelligence (AI) and machine learning (ML) to improve precision medicine. About Xencor Xencor develops modified antibodies and cytokines for cancer and autoimmune illnesses. More than 20 XmAb® candidates are in clinical development while three are sold by partners. The company’s XmAb technology modifies protein structures to create new therapeutic pathways.

Read More

More featured news